Angiogenesis

Background Angiogenesis is the process of growing blood vessels with various body organs. The sustainability of life depends on the accuracy and richness of the process. The cornea is a living tissue without blood vessels, as evidenced by its optical transparency transparency. Since the cornea is avascular, it is an excellent model for studying the mechanisms that promote or inhibit angiogenesis. By comparing the corneal tissue with other vascular tissues, a greater understanding of angiogenesis occurs, ultimately leading to the treatment of vascular diseases such as macular degeneration, tumor or ischemic heart disease.

Angiogenesis (angiogenesis) is an important part of the formation of large tumor masses. Angiogenesis can be inhibited by the expression of several genes that can be delivered to cancer cells in viral vectors, thereby inhibiting angiogenesis and oxygen starvation in tumors. When cells were infected with viruses containing angiostatin and endostatin genes, tumor growth of mice was suppressed. Enhanced antitumor activity has been demonstrated in recombinant vaccinia viruses encoding anti-angiogenic therapeutic antibodies and HSV 1716 mutants expressing angiogenesis inhibitors.

Diagram Tumor Angiogenesis Angiogenesis is initiated by the production of angiogenic factors from tumor cells such as vascular endothelial growth factor (VEGF). After binding to cognate receptors on endothelial cells, VEGF causes endothelial cell proliferation and migration. Degradation and invasion of the extracellular matrix (ECM), then bevacizumab binds all human VEGF-A and its Fab fragment with high affinity and selectively binds ligand VEGF before VEGF binds to native endothelial cell receptor Interaction. Antibody-dependent cellular cytotoxicity (ADCC). Conventional ligand-receptor interactions are blocked, receptor phosphorylation and downstream pathways are also activated. Therefore, angiogenesis is reduced and tumor angiogenesis and tumor growth are also inhibited (23). In vitro and in vivo assay systems bind to human VEGF and inhibit its biological activity (64).

For brain tumors, anti-angiogenic therapy is used as a targeted therapy, and other therapies are being studied. It focuses on preventing angiogenesis. That is the process of making a new blood vessel. The purpose of antiangiogenic therapy is to "starve" the tumor as tumors require nutrients to be transported from the blood vessels to grow and spread. Bevacizumab (Avastin, Mvasi) is an antiangiogenic therapy used to treat glioblastoma multiforme in the absence of previous therapy. Please consult your doctor about the side effects of certain medications and how to manage them